NCT07049978Completed
Long-term Effect of Dupilumab in N-ERD
Long-term Effect of Dupilumab on Acetylsalicylic Acid (ASA) Intolerance and Its Mechanisms in Patients With Non-steroidal Anti-inflammatory Drug-exacerbated Respiratory Disease (N-ERD)
Source: ClinicalTrials.gov · Last updated 7 Oct 2026
Brief summary (registry, in English)
This prospective observational study investigates the long-term effects of Dupilumab in patients with NSAID-exacerbated respiratory disease (N-ERD). The study assesses changes in ASA tolerance, clinical parameters, inflammatory biomarkers, quality of life, and nasal microbiome during ongoing treatment with Dupilumab. All participants are receiving Dupilumab as part of standard clinical care.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 15 (actual)
- First submitted
- 25 Jun 2025
- Start date
- 1 Sept 2025
- Primary completion date
- 7 May 2026
- Lead sponsor
- Medical University of Vienna
- Diseases
- Asthma
- NCT number
- NCT07049978
What you commit to
- Study type: Observational
- Participants enrolled: 15
- From 1 Sept 2025 to the primary completion date, 7 May 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Need for systemic corticosteroid therapy 1 month prior to screening visit
- Previous anaphylaxis and contraindications against ASA as outlined in the official prescribing information.
Other illness
- History of malignancy or immunodeficiency
- Chronic obstructive lung disorders (COPD), other obstructive lung disorders (bronchiolitis)
- Eosinophilic pneumonia and Churg-Strauss Syndrome
Lab values
- Clinically significant abnormal laboratory values and active infection (Tbc, HIV, hepatitis A/B/C)
Other
- Pregnancy (as determined by urine ß-HCG test)
Who the study is looking for
- Participated previously in our preliminary study (EK 1044/2020) and continued Dupilumab treatment since then. Long-term use of Dupilumab since the preliminary study will be assessed based on patient self-report, as there is currently no clinical test or laboratory parameter available to objectively verify treatment duration.
- Signed and dated informed consent has been obtained
- Current therapy with Dupilumab
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Medical University of Vienna Coordinator of this site? Confirm its status | Vienna | Austria | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.